Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial

PURPOSE: The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib vs. placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater in patients with ER+/HER2+ tumors. We thus sought to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Sudhan, Dhivya R., Schwarz, Luis J., Guerrero-Zotano, Angel, Formisano, Luigi, Nixon, Mellissa, Croessmann, Sarah, Ericsson, Paula I. González, Sanders, Melinda E., Balko, Justin M., Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Bryce, Richard, Auerbach, Alan, Arteaga, Carlos L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6444371/
https://ncbi.nlm.nih.gov/pubmed/30274983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1131
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados